insights_auto
Why is AMRN down 2.91%?
Dive Deeperchevron_right
AMRN:NASDAQ
Amarin Corporation PLC
$12.35
arrow_downward
-2.91%(-0.37) 1D
Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMRN...
Open
$13.00
High
$13.02
Low
$12.31
Mkt. cap
260.87M
Avg. vol.
73.53K
Volume
100.39K
52-wk high
$20.90
52-wk low
$12.31
EPS
-$1.30
Beta
0.76
Shares outstanding
21.12M
No. of employees
80
Open
$13.00
High
$13.02
Low
$12.31
Mkt. cap
260.87M
Avg. vol.
73.53K
Volume
100.39K
52-wk high
$20.90
52-wk low
$12.31
EPS
-$1.30
Beta
0.76
Shares outstanding
21.12M
No. of employees
80
News stories
From web sources and news partners
bloomingbit
·
10 minutes ago
UK’s OpenPayd Targets Nasdaq Listing This Year via Titan Acquisition Merger, Speeds US Expansion
Simply Wall Street
·
1 hour ago
What Had To Hold Up For OptimizeRx (OPRX) And What Broke First?
TradingKey
·
48 minutes ago
S&P 500 vs. Nasdaq 100: Which Is Better for Long-Term Investment?
Business Insider
·
17 hours ago
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
Profile
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
About Amarin Corporation PLC
CEO-
Employees80
FoundedMar 1, 1989
HeadquartersDublin, Leinster, Ireland
SectorBiotechnology
Websiteamarincorp.com